Ibidreid (Colecalciferol)

Colecalciferol is absorbed from the gut and converted in the liver to 25‑hydroxyvitamin D, then to the active hormone calcitriol in the kidneys. Calcitriol binds to the vitamin D receptor in intestinal cells, stimulating the production of calcium‑binding proteins that increase calcium and phosphate absorption, essential for bone mineralization.

The appropriate dose of Ibidreid is determined by the prescribing healthcare professional based on the patient’s age, baseline vitamin D status, and clinical needs. Dosage may be adjusted after laboratory monitoring of serum calcium and 25‑hydroxyvitamin D levels.

Safety data for colecalciferol in pregnancy and lactation are limited. Healthcare providers should evaluate the risk‑benefit profile for each individual. Women who are pregnant or breastfeeding should discuss use with their physician before starting therapy.

To order Ibidreid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibidreid provides colecalciferol, the same active ingredient found in most vitamin D3 supplements. Differences among products are usually related to dosage strength, formulation (tablet, capsule, liquid) and regulatory status. Clinical efficacy is comparable when equivalent doses are administered.

Store Ibidreid at room temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain stability.

Ibidreid is taken orally. Swallow the tablet whole with a glass of water. It may be taken with or without food, although taking it with a meal that contains fat can improve absorption of the fat‑soluble vitamin.

The most serious risks include hypercalcemia, which can cause cardiac arrhythmias, renal stones, and, in rare cases, severe allergic reactions. Patients should be monitored for signs of elevated calcium levels, especially if they have underlying conditions that affect calcium metabolism.

Ibidreid should be avoided in individuals with known hypersensitivity to colecalciferol or any excipients, those with existing hypercalcemia, severe renal impairment, or diseases such as sarcoidosis that alter vitamin D metabolism. A healthcare professional should assess suitability before initiating therapy.